Formulation, Characterization and Pharmacokinetic Evaluation of Naringenin- Loaded Gastroretentive Mucoadhesive Polymeric Nanosystem for Oral Drug Delivery

Suseela, Panneerselvam; Premkumar, Kumpati; Saraswathy, Sundara Dhakshinamurthy

doi:10.22270/jddt.v5i2.1091

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relative bioavailability of NGN-PLGA nanoparticles was found to be~1.7 times more as compared to naringenin suspension. Similar results were obtained by other research groups where there was increase in bioavailability of naringenin after its incorporation into delivery systems which enhance dissolution and prolong the circulation time because of their small size, bypassing the reticuloendothelial system (Ji et al 2016;Khan et al 2015;SUSEELA et al 2015). The results of brain to plasma ratio of the availability of the drug also indicated that there was enhanced uptake in the brain after incorporation of naringenin into nanoparticles.…”

Section: Brain:plasma Ratiosupporting

confidence: 85%

Development of a new, sensitive, and robust analytical and bio-analytical RP-HPLC method for in-vitro and in-vivo quantification of naringenin in polymeric nanocarriers

et al. 2019

View full text Add to dashboard Cite

Background: Naringenin is a flavanone having strong antioxidant potential. It is an anti-hyperlipidemic, antidepressant, anti-cancer, and neuroprotective agent. However, its major limitation is its low oral bioavailability. Objective: In order to overcome this limitation and to explore its antioxidant potential in autism spectrum disorders, we developed brain targeting PLGA nanocarriers of naringenin. Current study involves development of a sensitive and robust RP-HPLC method for detection and quantification (in vitro and in vivo) of naringenin in nanoparticles. Methods: An isocratic RP-HPLC method was developed using C 18 reversed-phase column (250 × 4.6 mm internal diameter and 5 μm particle size). Flow rate of mobile phase was 1 ml/min and temperature of column was 30°C. Methanol and 0.5% ortho-phosphoric acid in MilliQ water (pH 2) (70:30) was used as mobile phase. The ultraviolet detection wavelength for quantification was at 289 nm. Results: Calibration curve showed linearity within the concentration range from 0.5 to 40 μg/ml (R 2 = 1) for the analytical method and for plasma (6.3-200 ng/ml (R 2 = 0.9975)) and brain tissue samples (31.25-12,500 ng/ ml (R 2 = 1)). Limit of detection (LOD) and limit of quantification (LOQ) were 0.15 μg/ml and 0.44 μg/ml for the analytical method. For bio-analytical method, LOD and LOQ were 9.71 ng/ml and 29.44 ng/ml for plasma and 9.06 ng/ml and 27.44 ng/ml for brain sample. Both the method was precise, accurate, and robust. Bioanalytical method showed good recovery from plasma and brain samples (> 95%). Conclusion: This analytical and bio-analytical method was applied to detect entrapment efficiency, in-vitro release, and pharmacokinetic parameters of naringenin nanoparticles.

show abstract

Section: Brain:plasma Ratiosupporting

confidence: 85%

Development of a new, sensitive, and robust analytical and bio-analytical RP-HPLC method for in-vitro and in-vivo quantification of naringenin in polymeric nanocarriers

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Oral delivery [16] Curcumin NIPAAM/VP/PEG-A To improve the solubility of the drug Increased oral bioavailability Oral delivery [17] Rivastigmine Polysorbate- 80 To prolong the drug release Improved cognitive functions and memory Oral delivery [18] Polymeric micelles In vitro [25] Paclitaxel P(GLU)…”

Section: Phas-phbvsmentioning

confidence: 99%

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

et al. 2017

View full text Add to dashboard Cite

Degenerative diseases are results of deterioration of cells and tissues with aging either by unhealthy lifestyle or normal senescence. The degenerative disease likely affects central nervous system and cardiovascular system to a great extent. Certain medications and therapies have emerged for the treatment of degenerative diseases, but in most cases bearing with poor solubility, lower bioavailability, drug resistance, and incapability to cross the bloodbrain barrier (BBB). Hence, it has to be overcome with conventional treatment system; in this connection, nanotechnology has gained a great deal of interest in recent years. Moreover, nanotechnology and nanocarrier-based approach drug delivery system could revolutionize the treatment of degenerative diseases by faster absorption of drug, targeted interaction at specific site, and its release in a controlled manner into human body with minimal side effects. The core objective of this review is to customize and formulate therapeutically active molecules with specific site of action and without affecting other organs and tissues to obtain effective result in the improvement of quality of health. In addition, the review provides a concise insight into the recent developments and applications of nanotech and nanocarrier-based drug delivery for the treatment of various degenerative diseases.

show abstract

“…The area under the plasma concentration-time curve from zero to the last measurable plasma concentration (area under curve [AUC 0-t ]) was calculated by the linear trapezoidal rule. [22] Tissue distribution assay of NAR-NS NAR-S and NAR-NS were dispersed in water for oral administration (210 mg/kg twice daily) for 17 doses through gastric gavage which were administrated to 16 rats. Animals were euthanized at the time points of 10 min, 1 h, 3 h, and 6 h after dose (n = 4 at each time point).…”

Section: Determination Of Nar In Rabbit Plasma By Hplcmentioning

confidence: 99%

Untitled

Rajamani¹

2018

AJP

View full text Add to dashboard Cite

Aim: The purpose of this study was to investigate the pharmacokinetic properties and tissue biodistribution of naringenin nanosuspension (NAR-NS) with that of NAR solution (NAR-S) after oral administration. Materials and Methods: NAR is a major antioxidant flavonoid present in citrus fruits and herbs. It is an auspicious drug based on its good bioactivity, but the use of NAR is clinically hindered because of its poor solubility and bioavailability. Hence, it was formulated as a NS. A simple and rapid high-performance liquid chromatography method for the determination of NAR-S and NAR-NS present in plasma and tissue has been developed and validated. Biological samples were processed by simple protein precipitation. Results: NS formulation showed significantly improved solubility and oral bioavailability of NAR. Conclusion: Thus leads to a wider clinical application.

show abstract

Formulation, Characterization and Pharmacokinetic Evaluation of Naringenin- Loaded Gastroretentive Mucoadhesive Polymeric Nanosystem for Oral Drug Delivery

Cited by 4 publications

References 29 publications

Development of a new, sensitive, and robust analytical and bio-analytical RP-HPLC method for in-vitro and in-vivo quantification of naringenin in polymeric nanocarriers

Development of a new, sensitive, and robust analytical and bio-analytical RP-HPLC method for in-vitro and in-vivo quantification of naringenin in polymeric nanocarriers

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

Untitled

Contact Info

Product

Resources

About